Experience with enfuvirtide (fuzeon) in the treatment regimens for HIV infection


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The authors describe their experience with enfuvirtide (fuzeon) used in the inhospital treatment of HIV-infected comatous patients with a low (less than 50 cells/pl) CD4 lymphocyte count, who are unable to use medicinal tablets. For rescue therapy, patients were given antiretroviral agents as liquid formulations through a tube and subcutaneous enfuvirtide. The authors’ experience verifies that it is advisable to use enfuvirtide in combination with other antiretroviral agents: 1) in central nervous system dysfunction and inability to take medicinal tablets; 2) when administered as part of first-line antiretroviral therapy if there is a considerable immunosuppression (the count of CD4 lymphocytes is less than 50-100 cells/pl) and progression of life-threatening opportunistic infections (including tuberculosis); 3) as an induction regimen over 12-24 weeks.

全文:

受限制的访问

作者简介

E. Beketova

Center for AIDS Prevention and Control

Email: rostaids@aaanet.ru
Rostov-on-Don

S. Bykov

Center for AIDS Prevention and Control

Email: bykov_s_a_63@mail.ru
Rostov-on-Don

参考

  1. Eggink D., Berkhout B., Sanders R.W. Inhibition of HIV-1 by fusion inhibitors. Curr. Pharm. Des. 2010; 16(33): 3716-3728.
  2. Bonora S., Calcagno A., Cometto C. et al. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. Infection 2012; 40(1): 69-75.
  3. Joly V., Jidar K., Tatay M., Yeni P. Enfuvirtide: from basic investigations to current clinical use. Ехреrt Оріп. Pharmacother. 2010; 11(16): 2701-2713.
  4. Makinson A., Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr. Оріп. HIV AIDS 2009; 4(2): 150-158.
  5. Кравченко А.В., Канестри В.Г. Применение ингибитора слияния энфувиртида в схемах антиретровирусной терапии у больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2013; 1: 47-52.
  6. Cooper D., Gatell J., Rockstroh J. et al. and the BENCHMRK-1 Study Group. 48-week results from BENCHMRK-1, a phase III study of raltegravir in patients failing ART with tripleclass resistant HIV-1. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008. Boston, Mass. Abstract 788.
  7. Cahn P., Molina J.-M., Towner W., Peeters M., Vingerhoets J., Beets G. et al. 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virological response to etravirine (TMC125; ETR). In: 17th International AIDS Conference. 3-8 August 2008. Mexico City. Abstract TUPE0047.
  8. Lalezari J., Goodrich J., DeJesus E. et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. In: 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007. Los Angeles, California. Аbstract 104bLB.
  9. Мазус А.И., Каминский Г.Д., Зимина В.Н., Бессараб Т.П., Пронин А.Ю., Цыганова Е.В. и др. Национальные клинические рекомендации по диагностике и лечению ВИЧ-инфекции у взрослых. М., 2013.
  10. Шахгильдян В.И., Беляева В.В. Паллиативная помощь при ВИЧ/СПИДе. Руководство по оказанию паллиативной помощи людям, живущим с ВИЧ. М., 2007. 170 с.
  11. Ермак Т.Н., Кравченко А.В., Груздев Б.М. Вторичные заболевания у больных ВИЧ-инфекцией - 15-летнее наблюдение. Тер. архив 2004; 76: 18-20.
  12. Johnson M., Sabin C., Girardi E. Definition and epidemiology of late presentation in Europe. Antivir. Ther. 2010; 15(Suppl. 1): 3-8.
  13. When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
  14. Сборник статей науч-практ. конф. «Достижение региональной стратегии по обеспечению универсального доступа к профилактике, диагностике и лечению ВИЧ-инфекции в Ростовской области». Ростов-на-Дону, 2009.
  15. Кравченко А.В., Кузнецова А.В. Козырев О.А., Лукьянова В.А., Канестри В.Г., Зимина В.Н Ингибитор слияния энфувиртид в схемах АРВТ у больных с ВИЧ-инфекцией и туберкулезом. ВИЧ-инфекция и иммуносупрессии 2010; 2(4): 35-41.
  16. Lalezari J.P., Henry K., O’Hearn М., Montaner J.S.G., Piliero P.J., Trottier B. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 2003; 348: 2175-2185.
  17. Lazzarin A., Clotet B., Cooper D., Reynes J., Arastéh K., Nelson M. et al.; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 2003; 348: 2186-2195.
  18. Bartlett J., Salgo M., DeMasi R. Early viral load responses on enfuvirtide in heavily treatment-experienced patients. Program and abstracts of the 15th International AIDS Conference. July 11-16 2004. Bangkok, Thailand. Abstract TuPeB4484.
  19. Clotet B., Bellos N., Molina J.M., Cooper D., Goffard J.C., Lazzarin A. et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369(9568): 1169-1178.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##